CA2474156A1 - Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c) - Google Patents

Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c) Download PDF

Info

Publication number
CA2474156A1
CA2474156A1 CA002474156A CA2474156A CA2474156A1 CA 2474156 A1 CA2474156 A1 CA 2474156A1 CA 002474156 A CA002474156 A CA 002474156A CA 2474156 A CA2474156 A CA 2474156A CA 2474156 A1 CA2474156 A1 CA 2474156A1
Authority
CA
Canada
Prior art keywords
formula
compound
cyclopentyl
hydroxy
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002474156A
Other languages
English (en)
Other versions
CA2474156C (fr
Inventor
Montse Llinas-Brunet
Vida J. Gorys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002370396A external-priority patent/CA2370396A1/fr
Application filed by Individual filed Critical Individual
Priority to CA2474156A priority Critical patent/CA2474156C/fr
Publication of CA2474156A1 publication Critical patent/CA2474156A1/fr
Application granted granted Critical
Publication of CA2474156C publication Critical patent/CA2474156C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés de la formule (I) ou un sel pharmaceutiquement acceptable desdits composés. Dans ladite formule, R?1¿ est hydroxy ou NHSO¿2?R?1A¿ (R?1A¿ étant alkyle (C¿1-8?), cycloalkyle (C¿3-7?) ou {alkyle (C¿1-6?)-cycloalkyle (C¿3-7?)}, tous éventuellement substitués 1 à 3 fois par halo, cyano, nitro, O-alkyle ( C¿1-6?), amido, amino ou phényle; ou bien R?1A¿ est aryle C¿6? ou C¿10? éventuellement substitué 1 à 3 fois par halo, cyano, nitro, alkyle (C¿1-6?), O-alkyle ( C¿1-6?), amido, amino ou phényle); R?2¿ est cycloalkyle (C¿4-6?); R?3¿ est t-btuyle ou cycloalkyle (C¿5-6?); et R?4¿ est cycloalkyle (C¿4-6?). Les composés de l'invention sont utiles comme inhibiteurs de la protéase NS3 du VHC destinés au traitement de l'hépatite C.
CA2474156A 2002-02-01 2003-01-24 Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c) Expired - Fee Related CA2474156C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2474156A CA2474156C (fr) 2002-02-01 2003-01-24 Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002370396A CA2370396A1 (fr) 2002-02-01 2002-02-01 Tri-peptides inhibiteur de l'hepatite c
CA2,370,396 2002-02-01
CA2474156A CA2474156C (fr) 2002-02-01 2003-01-24 Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c)
PCT/CA2003/000090 WO2003064456A1 (fr) 2002-02-01 2003-01-24 Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c)

Publications (2)

Publication Number Publication Date
CA2474156A1 true CA2474156A1 (fr) 2003-08-07
CA2474156C CA2474156C (fr) 2011-09-20

Family

ID=32991607

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2474156A Expired - Fee Related CA2474156C (fr) 2002-02-01 2003-01-24 Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c)

Country Status (1)

Country Link
CA (1) CA2474156C (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009227A1 (fr) * 2005-07-20 2007-01-25 Boehringer Ingelheim International Gmbh Analogues de peptides inhibiteurs de l'hepatite c
US7939667B2 (en) 2003-05-21 2011-05-10 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939667B2 (en) 2003-05-21 2011-05-10 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
US8067438B2 (en) 2003-05-21 2011-11-29 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
WO2007009227A1 (fr) * 2005-07-20 2007-01-25 Boehringer Ingelheim International Gmbh Analogues de peptides inhibiteurs de l'hepatite c

Also Published As

Publication number Publication date
CA2474156C (fr) 2011-09-20

Similar Documents

Publication Publication Date Title
CA2498572A1 (fr) Peptides macrocycliques actifs contre le virus de l'hepatite c
JP2005529069A5 (fr)
CA2516016A1 (fr) Composes d'inhibition de l'hepatite c
RS67204A (en) Tripeptides having a hydroxyproline ether of a substituted quinoline for inhibition of ns3 (hepatitis c)
RS67004A (en) Macrocyclic peptides active against the hepatitis c virus
EP1599496B1 (fr) Analogues de peptides inhibiteurs de l'hepatite c
CA2445938A1 (fr) Tri-peptides inhibiteurs de l'hepatite c
RU2010123928A (ru) Хиноксалинсодержащие соединения в качестве ингибиторов вируса гепатита с
WO2004113365A3 (fr) Inhibiteurs de la tripeptide hepatite c serine protease
MY133719A (en) Hepatitis c inhibitor tri-peptides
JP2010515752A5 (fr)
WO2004072243A3 (fr) Inhibiteurs macrocycliques de la serine protease de l'hepatite c
WO2004093798A3 (fr) Composes macrocycliques de quinoxalinyle inhibant les serine proteases de l'hepatite c
WO2004014313A3 (fr) Combinaisons d'agents pharmaceutiques en tant qu'inhibiteurs de replication hcv
CA2486308A1 (fr) Inhibiteurs du virus de l'hepatite c
UA83046C2 (ru) Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
JP2010508361A5 (fr)
JP2002522554A5 (fr)
WO2005037860A3 (fr) Inhibiteurs de serine proteases, en particulier la ns3-ns4a protease du hcv
JP2012512169A5 (fr)
BR0305259A (pt) Inibidores de hcv ns5b polimerase
JP2010521482A5 (fr)
JP2010521481A5 (fr)
ATE250080T1 (de) Hcv ns3 proteaseinhibitoren
CA2474156A1 (fr) Tripeptides comprenant un hydroxyproline ether d'une quinoline substituee destines a inhiber ns3 (hepatite c)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150126